Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1952 1
1953 1
1954 1
1955 1
1957 1
1970 1
1973 2
1975 10
1976 6
1977 5
1978 6
1979 6
1980 2
1981 7
1982 17
1983 15
1984 14
1985 14
1986 16
1987 16
1988 21
1989 24
1990 22
1991 41
1992 43
1993 42
1994 50
1995 72
1996 80
1997 72
1998 99
1999 103
2000 126
2001 125
2002 152
2003 177
2004 209
2005 271
2006 326
2007 355
2008 437
2009 453
2010 584
2011 700
2012 805
2013 857
2014 878
2015 1069
2016 1361
2017 3409
2018 5587
2019 3118
2020 1979
2021 2281
2022 2419
2023 2317
2024 948

Text availability

Article attribute

Article type

Publication date

Search Results

28,782 results

Results by year

Filters applied: . Clear all
Page 1
Emerging Strategies for the Treatment of Small Cell Lung Cancer: A Review.
Petty WJ, Paz-Ares L. Petty WJ, et al. JAMA Oncol. 2023 Mar 1;9(3):419-429. doi: 10.1001/jamaoncol.2022.5631. JAMA Oncol. 2023. PMID: 36520421 Review.
Recently, immunotherapy-based regimens have become available for the management of SCLC, with 2 programmed cell death 1 ligand 1 inhibitors approved in combination with chemotherapy for first-line treatment of extensive-stage disease. ...Potential therapeutic strategies, i …
Recently, immunotherapy-based regimens have become available for the management of SCLC, with 2 programmed cell death 1 ligand 1 inhibitors …
Neurotheranostics: The Next Frontier for Health Span.
Losee MA, Seibyl JP, Kuo PH. Losee MA, et al. J Nucl Med Technol. 2023 Dec 5;51(4):266-270. doi: 10.2967/jnmt.123.265502. J Nucl Med Technol. 2023. PMID: 37586855 Review.
With an aging U.S. population, advancements in the treatment of Alzheimer disease (AD) and other neurodegenerative diseases are key to the maximization of health span. The recent approval of 2 antiamyloid antibodies, which decrease brain amyloid load, places us on the cusp …
With an aging U.S. population, advancements in the treatment of Alzheimer disease (AD) and other neurodegenerative diseases are key to the m …
Cervical arthroplasty: what does the labeling say?
Turel MK, Kerolus MG, Adogwa O, Traynelis VC. Turel MK, et al. Neurosurg Focus. 2017 Feb;42(2):E2. doi: 10.3171/2016.11.FOCUS16414. Neurosurg Focus. 2017. PMID: 28142245 Review.
METHODS The FDA-approved labels for each of the 7 artificial discs were obtained from the official FDA website. These labels were meticulously compared with regard to the statistical analysis performed, the safety and efficacy data, and the randomized controlled trial that …
METHODS The FDA-approved labels for each of the 7 artificial discs were obtained from the official FDA website. These labels were met …
Behavioral Treatments for Post-Traumatic Headache.
Fraser F, Matsuzawa Y, Lee YSC, Minen M. Fraser F, et al. Curr Pain Headache Rep. 2017 May;21(5):22. doi: 10.1007/s11916-017-0624-x. Curr Pain Headache Rep. 2017. PMID: 28283812 Review.
Thus, we sought to examine the biopsychosocial factors that influence PTH and the non-pharmacologic treatments studied for headache treatment. ...There are few high quality studies on the non-pharmacologic treatments for PTH. Thermal and EMG biofeedback appear to have been …
Thus, we sought to examine the biopsychosocial factors that influence PTH and the non-pharmacologic treatments studied for headache t …
History, status, and politicization of the FDA.
Wang W, Wertheimer AI. Wang W, et al. Res Social Adm Pharm. 2022 May;18(5):2811-2816. doi: 10.1016/j.sapharm.2021.06.009. Epub 2021 Jun 26. Res Social Adm Pharm. 2022. PMID: 34215537
First passed by Congress in 1992, the Prescription Drug User Fee Act (PDUFA) allowed the Food and Drug Administration (FDA) to collect fees from drug manufacturers to fund new drug approvals. The law allowed the FDA to expedite drug approvals, but possibly lowered s …
First passed by Congress in 1992, the Prescription Drug User Fee Act (PDUFA) allowed the Food and Drug Administration (FDA) to collect fees …
Lead-like Drugs: A Perspective.
Raymer B, Bhattacharya SK. Raymer B, et al. J Med Chem. 2018 Dec 13;61(23):10375-10384. doi: 10.1021/acs.jmedchem.8b00407. Epub 2018 Jul 27. J Med Chem. 2018. PMID: 30052440 Review.
Lead-like drugs, or drugs below molecular weight 300, are an important and sometimes overlooked component of the current pharmacopeia and contemporary medicinal chemistry practice. To examine the recent state-of-the-art in lead-like drug discovery, we surveyed recent drug …
Lead-like drugs, or drugs below molecular weight 300, are an important and sometimes overlooked component of the current pharmacopeia and co …
Drug approval and drug effectiveness.
Spielmans GI, Kirsch I. Spielmans GI, et al. Annu Rev Clin Psychol. 2014;10:741-66. doi: 10.1146/annurev-clinpsy-050212-185533. Epub 2013 Dec 9. Annu Rev Clin Psychol. 2014. PMID: 24329178 Review.
The US Food and Drug Administration (FDA) reviews such data in determining whether to approve new treatments, and the published literature serves as a repository for evidence on treatment benefits and harms. We describe the FDA review of clinical trials, examining t …
The US Food and Drug Administration (FDA) reviews such data in determining whether to approve new treatments, and the published liter …
The Challenges of Pediatric Drug Development.
Rose K. Rose K. Curr Ther Res Clin Exp. 2019 Jan 26;90:128-134. doi: 10.1016/j.curtheres.2019.01.007. eCollection 2019. Curr Ther Res Clin Exp. 2019. PMID: 31388368 Free PMC article. Review.
Clinical centers, investigators, and IRBs/ECs should more carefully examine studies for unjustified regulatory demands, prevention of subjects' access to superior treatments, and undeclared COI's. Questionable studies should not be approved and ongoing ones should b …
Clinical centers, investigators, and IRBs/ECs should more carefully examine studies for unjustified regulatory demands, prevention of …
Ethical and regulatory implications of the COVID-19 pandemic for the medical devices industry and its representatives.
Blakely B, Rogers W, Johnson J, Grundy Q, Hutchison K, Clay-Williams R, Richards B, Maddern G. Blakely B, et al. BMC Med Ethics. 2022 Mar 23;23(1):31. doi: 10.1186/s12910-022-00771-2. BMC Med Ethics. 2022. PMID: 35321720 Free PMC article. Review.
Given the relatively low evidence standards currently required for regulatory approval of devices, this further indefinite reduction in standards raises serious ethical issues. Second, the pandemic has disrupted the usual operations of device representatives in hospitals, …
Given the relatively low evidence standards currently required for regulatory approval of devices, this further indefinite reduction …
FDA efficiency for approval process of COVID-19 therapeutics.
Cassidy C, Dever D, Stanbery L, Edelman G, Dworkin L, Nemunaitis J. Cassidy C, et al. Infect Agent Cancer. 2020 Dec 1;15(1):73. doi: 10.1186/s13027-020-00338-z. Infect Agent Cancer. 2020. PMID: 33292374 Free PMC article. Review.
Remdesivir, an investigational drug, and hydroxyloroquine, an FDA-approved drug for autoimmune diseases, were the two early potential therapies. This review article examines the expedited FDA review process for remdesivir and hydroxychloroquine, and analyzes data an …
Remdesivir, an investigational drug, and hydroxyloroquine, an FDA-approved drug for autoimmune diseases, were the two early potential …
28,782 results
You have reached the last available page of results. Please see the User Guide for more information.